TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25009252
Drug: Tonic pain
Normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonic pain during locomotor adaptation task (capsaicin cream applied around the ankle) on Day 1
Study: 12463730
Drug: rosuvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin (40 mg once daily)
Study: 10367540
Drug: Gemcitabine (1.000/1.250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1.000/1.250 mg/m2, administered on days 1, 8, 15 every 4 weeks)
Study: 7478688
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg/day for 4 weeks, increased to 40 mg if no marked improvement after 4 weeks
Study: 2110198
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium (200 mg orally four times per day)
Study: 27018464
Drug: Sequential use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential use of Foley balloon followed by oxytocin
Study: 24946565
Drug: Tripterygium glycosides
Normalized name: anthraquinone glycoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium glycosides (20 mg, three times a day for three months)
Study: 24946565
Drug: Prednisone (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (0.75 mg kg-1 d-1, gradually reduced to 5 mg d-1)
Study: 15813763
Drug: Weekly Browsing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly Browsing Journal Club (WBJC)
Study: 10601505
Drug: Efavirenz (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz (600 mg daily) plus zidovudine (300 mg twice daily) and lamivudine (150 mg twice daily)
Study: 10601505
Drug: Indinavir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir (800 mg every eight hours) plus zidovudine and lamivudine
Study: 10601505
Drug: Efavirenz plus
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz plus indinavir (1000 mg every eight hours)
Study: 10601505
Drug: Indinavir and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir and two nucleoside reverse‐transcriptase inhibitors
Study: 10601505
Drug: Efavirenz and
Normalized name: Efavirenz and lamivudine and tenofovir only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz and two nucleoside reverse‐transcriptase inhibitors
Study: 8720308
Drug: Lumbricus spencer,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbricus spencer, single oral dose of 500 mg
Study: 8720308
Drug: Lumbricus spencer,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbricus spencer, 1500 mg/d for one week
Study: 3698511
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion at incremental rates (4, 10, 25, and 62.5 ng min‐1 kg‐1)
Study: 3698511
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion at highest rate
Study: 27150080
Drug: Methylphenidate (20
Normalized name: methylphenidate (20/80 release) 25 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (20 mg oral)
Study: 24666893
Drug: Basic root
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic root canal treatment (BRT) with tactile working length determination
Study: 24666893
Drug: Standard endodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard endodontic treatment with radiographic working length control
Study: 22563844
Drug: Randomized assignment
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized assignment to treatment
Study: 19651669
Drug: Combination (arm-ergometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (arm-ergometry + treadmill)
Study: 17853009
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day for 1 month
Study: 15077098
Drug: Ticlopidine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine and aspirin
Study: 12603500
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg/day for 12 months
Study: 1748138
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg hCT
Study: 1748138
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg hCT
Study: 6763404
Drug: Antihypertensive pharmacotherapy
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive pharmacotherapy
Study: 26983164
Drug: Acetaminophen/paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen/paracetamol
Study: 16812974
Drug: Simvastatin 20-40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20-40 mg
Study: 15301218
Drug: Novel oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel oral water irrigator
Study: 1809419
Drug: Neutral hypnotic
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral hypnotic control condition
Study: 6218097
Drug: mezlocillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: mezlocillin (4 g 6-hourly)
Study: 6218097
Drug: carbenicillin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: carbenicillin (5 g 4-hourly)
Study: 30660371
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of lavender oil
Study: 28930494
Drug: Momelotinib 200
Normalized name: momelotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Momelotinib 200 mg once daily
Study: 28930494
Drug: Ruxolitinib 20
Normalized name: ruxolitinib 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 20 mg twice a day
Study: 23838316
Drug: OCDC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCDC vaccine (dendritic cells pulsed with HOCl-oxidized autologous tumor lysate)
Study: 21219979
Drug: Pandemic (H1N1)
Normalized name: pangamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pandemic (H1N1) 2009 vaccine containing 7.5 μg of hemagglutinin (HA)
Study: 21219979
Drug: Pandemic (H1N1)
Normalized name: pangamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pandemic (H1N1) 2009 vaccine containing 15 μg of hemagglutinin (HA)
Study: 21219979
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of A H1N1 vaccine
Study: 21219979
Drug: Pandemic (H1N1)
Normalized name: pangamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pandemic (H1N1) 2009 vaccine formulations
Study: 19809382
Drug: Chemotherapy-induced relative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-induced relative change signatures (TDelta)
Study: 12324295
Drug: Flour fortified
Normalized name: Flours
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flour fortified with iron only (60 mg Fe/kg)
Study: 12324295
Drug: Flour cofortified
Normalized name: Flours
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flour cofortified with zinc sulfate (60 mg Zn/kg)
Study: 12324295
Drug: Flour cofortified
Normalized name: Flours
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flour cofortified with zinc oxide (60 mg Zn/kg)
Study: 9880768
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy with radioisotope implantation
Study: 31194613
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg/d (neoadjuvant therapy for 42 days; adjuvant therapy for up to 12 months)
Study: 31194613
Drug: Gemcitabine 1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,250 mg/m2 plus cisplatin 75 mg/m2 (neoadjuvant therapy for two cycles; adjuvant therapy for up to two cycles)
Study: 21521254
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide LAR 20 mg every 28th day for 6 months
Study: 16925701
Drug: Control eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control eye drops (tropicamide, phenylepherine, atropine) administered as routine practice
Study: 10722780
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (PLA)
Study: 3979676
Drug: Cimetidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (20 mg/kg/24 h)
Study: 27224474
Drug: CD64-guided group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD64-guided group (antibiotics prescribed based on CD64 index)
Study: 27224474
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment group (antibiotics prescribed based on experience and clinical symptoms)
Study: 19736368
Drug: Aerosolized L-epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized L-epinephrine
Study: 11854876
Drug: Heparin-bonded cardiopulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded cardiopulmonary bypass (HB-CPB)
Study: 7566580
Drug: Intravenous calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous calcitriol (0.045 micrograms/kg/weekly)
Study: 7566580
Drug: Intermittent oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent oral calcitriol (0.045 micrograms/kg/weekly)
Study: 7566580
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral calcitriol (0.045 micrograms/kg/weekly)
Study: 1981436
Drug: Topical clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clindamycin phosphate 1% twice daily
Study: 1981436
Drug: Oral minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral minocycline 50 mg twice daily
Study: 7029294
Drug: 4 drugs
Normalized name: copper
DrugBank: Copper (DB09130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 drugs (vincristine, dactinomycin, cyclophosphamide, adriamycin)
Study: 7029294
Drug: 3 drugs
Normalized name: goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 drugs (vincristine, dactinomycin, cyclophosphamide)
Study: 7029294
Drug: 3 drugs
Normalized name: goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 drugs and bilateral pulmonary irradiation (approximately 1,500 rad in 2 weeks)
Study: 7029294
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) doses to the primary tumor
Study: 30939480
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group (systolic blood pressure target of < 120 mm Hg)
Study: 30939480
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group (systolic blood pressure target of < 140 mm Hg)
Study: 25919263
Drug: Active pulsed
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active pulsed electromagnetic field therapy
Study: 25919263
Drug: Sham pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham pulsed electromagnetic field therapy
Study: 21851939
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg on cycle days 3-7)
Study: 21851939
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (50 mg on cycle days 5-9)
Study: 7641905
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE) alone (0.625 mg daily)
Study: 7641905
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE) plus medrogestone (5 mg during the last 12 days of each 28-day cycle)
Study: 2653402
Drug: colchicine 0.5
Normalized name: colchicine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: colchicine 0.5 mg bd for 1 week
Study: 943169
Drug: Urea-lactic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea-lactic acid ointment
Study: 16499489
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of long-acting naltrexone 380 mg
Study: 16499489
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of long-acting naltrexone 380 mg every 28 days for a total of 4 doses
Study: 16499489
Drug: Oral naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naltrexone 50 mg daily for 5 days followed by IM long-acting naltrexone 380 mg
Study: 16499489
Drug: Oral naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naltrexone 50 mg
Study: 11360489
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nifedipine administered sublingually with a hole in it
Study: 11360489
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nifedipine administered intranasally with a syringe
Study: 11360489
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nifedipine administered orally (contents administered orally)
Study: 11360489
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nifedipine (capsule bitten and swallowed)
Study: 29931216
Drug: Romosozumab 210
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romosozumab 210 mg subcutaneously monthly for 12 months
Study: 16200586
Drug: Clofazimine (CFZ)
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clofazimine (CFZ) at 100 mg/day
Study: 16200586
Drug: Chloroquine diphosphate
Normalized name: CHLOROQUINE DIPHOSPHATE, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine diphosphate (CDP) at 250 mg/day
Study: 10895850
Drug: Repaglinide/troglitazone combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide/troglitazone combination therapy
Study: 10895850
Drug: Troglitazone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone monotherapy
Study: 8795325
Drug: Injection pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection pressure of 250 g.cm‐2 (group 2)
Study: 8795325
Drug: Injection pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection pressure of 140 g.cm‐2 (group 1)
Study: 1354566
Drug: terfenadine 120
Normalized name: terfenadine 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 120 mg (Triludan Forte)
Study: 1354566
Drug: cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cetirizine 10 mg (Zirtek)
Study: 28937862
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral carbohydrate (Nutricia Preop; n = 45)
Study: 16111583
Drug: Moderate rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate rectal radiation doses
Study: 12825239
Drug: Sulpiride (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (50 mg, three times per day for three months)
Study: 12825239
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered three times per day for three months)
Study: 1900383
Drug: Diet M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet M (70 g sunflower margarine, P:S 1.1)
Study: 1900383
Drug: Diet B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet B (70 g butter, P:S 0.2)
Study: 6860528
Drug: Diclofensine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofensine 25 mg and 50 mg
Study: 31735591
Drug: 10% povidone
Normalized name: POVIDONE-IODINE 100 mg in 1 mL TOPICAL LIQUID [Saninta 10% Povidone-Iodine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% povidone iodine preparation (single application)
Study: 31735591
Drug: Twice-daily treatment
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily treatment for 5 days with 10% povidone iodine
Study: 31285147
Drug: Opicinumab 3
Normalized name: Opicinumab
DrugBank: Opicinumab (DB14959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicinumab 3 mg/kg
Study: 31285147
Drug: Opicinumab 10
Normalized name: Opicinumab
DrugBank: Opicinumab (DB14959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicinumab 10 mg/kg
Study: 31285147
Drug: Opicinumab 30
Normalized name: Opicinumab
DrugBank: Opicinumab (DB14959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicinumab 30 mg/kg
Study: 31285147
Drug: Opicinumab 100
Normalized name: Opicinumab
DrugBank: Opicinumab (DB14959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicinumab 100 mg/kg
Study: 24914426
Drug: Cervitec Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervitec Plus (1% chlorhexidine‐1% thymol varnish) + Cervitec Gel (0.2% chlorhexidine‐0.2% sodium fluoride)
Study: 22076422
Drug: Atorvastatin 80mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80mg, ezetimibe 10mg (Group A)
Study: 11128860
Drug: 38 mg
Normalized name: alloin 38 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38 mg x kg(‐1) x d(‐1)
Study: 11128860
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg x kg(‐1) x d(‐1)
Study: 11128860
Drug: 76 mg
Normalized name: menthol 76 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 76 mg x kg(‐1) x d(‐1)
Study: 9191523
Drug: Recombinant interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant interferon-alpha (IFN-alpha) at a dose of 3 MU given intramuscularly 3 times a week for 6 months with a 1-month interval between cycles.
Study: 1554195
Drug: ICI 204219
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 204219 (20 mg)
Study: 3927279
Drug: Metoclopramide (dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (dopamine receptor blocker)
Study: 20585108
Drug: KNO3 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: KNO3 capsules (4 mmol, 12 mmol, or 24 mmol)
Study: 20585108
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (250 mL, 5.5 mmol nitrate)
Study: 18568474
Drug: Ice-cream containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice-cream containing Bifidobacterium lactis Bb-12
Study: 18568474
Drug: Control ice-cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control ice-cream without viable bacteria
Study: 16353677
Drug: Hair removal
Normalized name: Kendra SKIN PROTECTION and PAIN RELIEF FOR HAIR REMOVAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hair removal by clipper or depilatory cream
Study: 12050273
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (24 mg/ml)
Study: 8721040
Drug: Strawberry flavor
Normalized name: Strawberry Flavor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strawberry flavor of ondansetron syrup
Study: 8721040
Drug: Grape flavor
Normalized name: Grape Flavor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape flavor of ondansetron syrup
Study: 1757606
Drug: 0.05% halobetasol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% halobetasol propionate ointment
Study: 795190
Drug: 0.1% diflucortolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% diflucortolone valerate ointment
Study: 25512466
Drug: Allopurinol 500
Normalized name: allopurinol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 500 mg intravenous (ALLO)
Study: 25512466
Drug: Placebo intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous (CONT)
Study: 23074122
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) with propofol
Study: 20802165
Drug: Written action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written action plan coupled with a prescription (WAP-P)
Study: 20802165
Drug: Unformatted prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unformatted prescription (UP)
Study: 18034777
Drug: Conivaptan 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conivaptan 40 mg/day
Study: 18034777
Drug: Conivaptan 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conivaptan 80 mg/day
Study: 10199774
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at a mean dose of 1 UI/day for 1 year
Study: 10199774
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at a mean dose of 1 UI/day for 2 years
Study: 8568547
Drug: Tobramycin 150
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin 150 or 300 mg administered intramuscularly (i.m.)
Study: 8568547
Drug: Tobramycin 300
Normalized name: TOBRAMYCIN 300MG/5ML SOLN,INHL,KIT 56
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin 300 mg administered intramuscularly (i.m.)
Study: 2269380
Drug: Topical MC
Normalized name: MC-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical MC 903 ointment (50 micrograms/g) alone
Study: 2269380
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of topical MC 903 with UVB radiation
Study: 2269380
Drug: Control (Topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Topical MC 903 alone)
Study: 2269380
Drug: Control (Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Combination with UVB)
Study: 23700406
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin administration over an 8-week period
Study: 20530042
Drug: 12-week supervised
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week supervised exercise intervention followed by 12 weeks of self-administered exercise
Study: 16997602
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of a single 2 ml dose of hylan G-F 20 into the hip joint under fluoroscopic guidance.
Study: 15598477
Drug: Galantamine 8
Normalized name: galantamine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 8 mg/d